{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:52:16Z","timestamp":1773298336336,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,3]],"date-time":"2020-01-03T00:00:00Z","timestamp":1578009600000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010621","name":"Uniwersytet Medyczny w Lublinie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.pbb.2019.172833","type":"journal-article","created":{"date-parts":[[2019,11,27]],"date-time":"2019-11-27T11:38:44Z","timestamp":1574854724000},"page":"172833","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Influence of the CB1 and CB2 cannabinoid receptor ligands on the activity of atypical antidepressant drugs in the behavioural tests in mice"],"prefix":"10.1016","volume":"188","author":[{"given":"Ewa","family":"Poleszak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylwia","family":"Wo\u015bko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"S\u0142awi\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"El\u017cbieta","family":"Wyska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Szopa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"\u015awi\u0105der","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Wr\u00f3bel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urszula","family":"Doboszewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Wla\u017a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Wla\u017a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Serefko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2019.172833_bb0005","first-page":"217","article-title":"Activation of endocannabinoid transmission induces antidepressant-like effects in rats","volume":"59","author":"Adamczyk","year":"2008","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.pbb.2019.172833_bb0010","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/npp.2010.80","article-title":"Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus","volume":"35","author":"Bambico","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2019.172833_bb0015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/sj.bjp.0707505","article-title":"Cannabinoid CB2 receptors in human brain inflammation","volume":"153","author":"Benito","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2019.172833_bb0020","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.nbd.2010.03.020","article-title":"Depression-like phenotype following chronic CB1 receptor antagonism","volume":"39","author":"Beyer","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.pbb.2019.172833_bb0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/157488906775245327","article-title":"Tianeptine: a novel atypical antidepressant that may provide new insights into the biomolecular basis of depression","volume":"1","author":"Brink","year":"2006","journal-title":"Recent Pat CNS Drug Discov"},{"key":"10.1016\/j.pbb.2019.172833_bb0030","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1080\/14656566.2016.1219340","article-title":"Current pharmacotherapy of depression - focused on multimodal\/multifunctional antidepressants","volume":"17","author":"Ceskova","year":"2016","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.pbb.2019.172833_bb0035","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.neubiorev.2005.03.009","article-title":"The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice","volume":"29","author":"Cryan","year":"2005","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.pbb.2019.172833_bb0040","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.pnpbp.2011.11.007","article-title":"Effects induced by cannabinoids on monoaminergic systems in the brain and their implications for psychiatric disorders","volume":"38","author":"Esteban","year":"2012","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172833_bb0045","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ibror.2019.01.001","article-title":"The emergence of new antidepressants for clinical use: agomelatine paradox versus other novel agents","volume":"6","author":"Fasipe","year":"2019","journal-title":"IBRO Rep"},{"key":"10.1016\/j.pbb.2019.172833_bb0050","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.euroneuro.2012.06.012","article-title":"Cannabinoid 2 receptor- and beta Arrestin 2-dependent upregulation of serotonin 2A receptors","volume":"23","author":"Franklin","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.pbb.2019.172833_bb0055","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/j.1476-5381.2010.00819.x","article-title":"Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors","volume":"160","author":"Garc\u00eda-Guti\u00e9rrez","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2019.172833_bb0060","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.biopsych.2004.10.032","article-title":"Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents","volume":"57","author":"Griebel","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172833_bb0065","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1111\/bph.12720","article-title":"Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties","volume":"171","author":"Guardiola-Lemaitre","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pbb.2019.172833_bb0070","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.neuropharm.2012.09.002","article-title":"Cannabinoid CB(1) receptor in the modulation of stress coping behavior in mice: the role of serotonin and different forebrain neuronal subpopulations","volume":"65","author":"H\u00e4ring","year":"2013","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2019.172833_bb0075","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1360-0443.2012.04078.x","article-title":"Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings","volume":"108","author":"Hermanns-Clausen","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.pbb.2019.172833_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23081836","article-title":"Cannabinoid CB2 receptor gene and environmental interaction in the development of psychiatric disorders","volume":"23","author":"Ishiguro","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.pbb.2019.172833_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108717","article-title":"Ketamine-induced antidepressant like effects in mice: a possible involvement of cannabinoid system","volume":"112","author":"Khakpai","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.pbb.2019.172833_bb0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.bbr.2015.01.051","article-title":"Antidepressant-like effects of the cannabinoid receptor ligands in the forced swimming test in mice: mechanism of action and possible interactions with cholinergic system","volume":"284","author":"Kruk-S\u0142omka","year":"2015","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.pbb.2019.172833_bb0095","doi-asserted-by":"crossref","first-page":"L109","DOI":"10.1016\/S0024-3205(97)01187-9","article-title":"AM630 is an inverse agonist at the human cannabinoid CB1 receptor","volume":"62","author":"Landsman","year":"1998","journal-title":"Life Sci."},{"key":"10.1016\/j.pbb.2019.172833_bb0100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neuropharm.2015.12.017","article-title":"Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT\/glutamate neurotransmission: role of 5-HT1A receptors","volume":"103","author":"Linge","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2019.172833_bb0105","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/mp.2009.80","article-title":"The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation","volume":"15","author":"McEwen","year":"2010","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pbb.2019.172833_bb0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ejphar.2009.09.055","article-title":"Monoaminergic neurotransmission contributes to cannabinoid-induced activation of the hypothalamic-pituitary-adrenal axis","volume":"624","author":"McLaughlin","year":"2009","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2019.172833_bb0115","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1590\/S1516-44462009000200012","article-title":"The psychiatric side-effects of rimonabant","volume":"31","author":"Moreira","year":"2009","journal-title":"Braz J Psychiatry"},{"key":"10.1016\/j.pbb.2019.172833_bb0120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.beem.2008.09.003","article-title":"Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression","volume":"23","author":"Moreira","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.pbb.2019.172833_bb0125","article-title":"Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects","volume":"20","author":"Onaivi","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.pbb.2019.172833_bb0130","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/1440-1681.12518","article-title":"Involvement of opioid system in antidepressant-like effect of the cannabinoid CB1 receptor inverse agonist AM-251 after physical stress in mice","volume":"43","author":"Ostadhadi","year":"2016","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.pbb.2019.172833_bb0135","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/978-3-540-88955-7_14","article-title":"Role of endocannabinoid signaling in anxiety and depression","volume":"1","author":"Patel","year":"2009","journal-title":"Curr. Top. Behav. Neurosci."},{"key":"10.1016\/j.pbb.2019.172833_bb0140","series-title":"Handbook of Experimental Pharmacology","article-title":"Endocannabinoids","year":"2015"},{"key":"10.1016\/j.pbb.2019.172833_bb0145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.brainresbull.2019.05.021","article-title":"Influence of the CB1 cannabinoid receptors on the activity of the monoaminergic system in the behavioural tests in mice","volume":"150","author":"Poleszak","year":"2019","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.pbb.2019.172833_bb0150","first-page":"327","article-title":"Behavioral despair in mice: a primary screening test for antidepressants","volume":"229","author":"Porsolt","year":"1977","journal-title":"Arch. Int. Pharmacodyn. Ther."},{"key":"10.1016\/j.pbb.2019.172833_bb0155","doi-asserted-by":"crossref","DOI":"10.1177\/2045125319855206","article-title":"What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice?","volume":"9","author":"Potm\u011b\u0161il","year":"2019","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.pbb.2019.172833_bb0160","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/00008877-200312000-00001","article-title":"Antidepressant-like and anorectic effects of the cannabinoid CB1 receptor inverse agonist AM251 in mice","volume":"14","author":"Shearman","year":"2003","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.pbb.2019.172833_bb0165","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.neuro.2017.08.012","article-title":"Changes in the cannabinoids receptors in rats following treatment with antidepressants","volume":"63","author":"Smaga","year":"2017","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.pbb.2019.172833_bb0170","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00428203","article-title":"The tail suspension test: a new method for screening antidepressants in mice","volume":"85","author":"Steru","year":"1985","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2019.172833_bb0175","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.pharep.2019.03.007","article-title":"Agomelatine and tianeptine antidepressant activity in mice behavioral despair tests is enhanced by DMPX, a selective adenosine A2A receptor antagonist, but not DPCPX, a selective adenosine A1 receptor antagonist","volume":"71","author":"Szopa","year":"2019","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.pbb.2019.172833_bb0180","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejphar.2008.05.020","article-title":"Additive subthreshold dose effects of cannabinoid CB(1) receptor antagonist and selective serotonin reuptake inhibitor in antidepressant behavioral tests","volume":"589","author":"Takahashi","year":"2008","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pbb.2019.172833_bb0185","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3109\/13651501.2013.798418","article-title":"Possible usefulness of tianeptine in treatment-resistant depression","volume":"17","author":"Tobe","year":"2013","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.pbb.2019.172833_bb0190","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1111\/bph.12607","article-title":"Regulatory role of the cannabinoid CB2 receptor in stress-induced neuroinflammation in mice","volume":"171","author":"Zoppi","year":"2014","journal-title":"Br. J. Pharmacol."}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305719304873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305719304873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:35:37Z","timestamp":1758774937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305719304873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":38,"alternative-id":["S0091305719304873"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2019.172833","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of the CB1 and CB2 cannabinoid receptor ligands on the activity of atypical antidepressant drugs in the behavioural tests in mice","name":"articletitle","label":"Article Title"},{"value":"Pharmacology Biochemistry and Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pbb.2019.172833","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"172833"}}